CSF Europe 2024 - Compaction Simulation Forum

��ɫAV

Start

Tuesday, June 04, 2024 - 16:49

End

Thursday, June 06, 2024 - 18:00

Location: Dublin, Ireland

CSF Conference João Henriques speaker | ��ɫAV

CSF Workshop: Overcoming The Challenge of Poorly Soluble Drugs

This workshop delves into the complexities surrounding the formulation of poorly soluble drugs, a prevalent concern affecting a significant percentage of active pharmaceutical ingredients. Explore the scientific nuances of amorphous forms and their role in amorphous solid dispersions (ASDs), offering insights into enhanced solubility and dissolution.��

Our expert, João Henriques, Director, Oral Drug Product Development will lead the Workshop Session: Process Development and Scale-Up of Spray Drying

Join the session for an academic exploration where knowledge converges with scientific rigor, providing a thorough understanding of the formulation intricacies of poorly soluble drugs.
��
Key learnings:

Expand on your foundations and principles of spray drying for ASDs, from lab-scale development tools to the scale-up of processes and gain valuable insights on how ASDs improve the solubility and bioavailability of poorly soluble drugs.
Overcome solubility challenges with the best scale-up science, utilizing mechanistic and statistical modeling to delve into the impact of spray drying conditions and material attributes on downstream processing while leveraging our extensive expertise to ensure success from lab-scale to commercialization.

��

Do you want to know how ��ɫAV can support your project? today.

��

Learn more about .

��

Lisbon, Portugal – ��ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ��ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ��ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ��ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ��ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ��ɫAV’s sustainability ambitions. ��ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating. Learn more about Science Based-Targets

News

��ɫAV commitment to setting SBTs in line with the Paris Agreement

��ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

��ɫAV

Browser not supported

Press Room